- Home
- RIGL vs SPFI Comparison
RIGL vs SPFI Comparison
Compare RIGL & SPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | SPFI |
|---|---|---|
| Founded | 1996 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 820.1M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RIGL | SPFI |
|---|---|---|
| Price | $48.73 | $43.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $63.00 | $50.50 |
| AVG Volume (30 Days) | ★ 187.8K | 78.6K |
| Earning Date | 11-03-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | ★ 1867.68 | 17.81 |
| EPS | 1.32 | ★ 1.82 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | $17.77 |
| Revenue Next Year | $21.95 | $8.74 |
| P/E Ratio | $37.03 | ★ $23.85 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $35.34 |
| 52 Week High | $52.24 | $46.94 |
Technical Indicators
Market Signals| Indicator | RIGL | SPFI |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 54.45 |
| Support Level | $44.50 | $42.76 |
| Resistance Level | $50.19 | $44.13 |
| Average True Range (ATR) | 1.83 | 0.84 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 66.42 | 73.36 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.